Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Enveric Biosciences Inc (ENVB) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance

Enveric Biosciences IncTrade
Health Care Select Sector SPDR FundTrade

Price performance (Past 24H)

Key statistics

Enveric Biosciences Inc vs Health Care Select Sector SPDR Fund — how do they compare? Enveric Biosciences Inc trades at $1.59 (market cap $6.20M), while Health Care Select Sector SPDR Fund trades at $168.49. The key difference: Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.

ENVBXLV
Market Cap
$6.20M
Sector
Health
52-Week High
$17.40$168.44
52-Week Low
$1.27$131.16
Enterprise Value
$1.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Enveric Biosciences Inc

ENVB trades at $1.59, up 3.25% today, with a bullish technical signal driven by moving averages. The company, a biotechnology firm developing neuroplastogenic therapeutics, reported significant earnings beats in all quarters of 2025, including a positive EPS of $0.85 in Q4 versus an expected loss. Recent news highlights progress with its lead candidate EB-003, including non-hallucinogenic profile confirmations and FDA guidance alignment, though financials show negative ROE and ROA with net income of -$8.77M in 2025.

The outlook is cautiously optimistic due to strong analyst support (75% buy ratings) and clinical advancements, but high financial losses and reliance on financing cash flow pose risks. Stock performance hinges on successful drug development milestones and future profitability, with current sentiment buoyed by technical strength and positive pipeline updates.

Health Care Select Sector SPDR Fund

XLV, the Health Care Select Sector SPDR ETF, trades at $167.93, down 0.3% on the day, with a bullish technical signal driven by moving averages. The ETF offers broad healthcare exposure with a low expense ratio of 0.08% and a trailing dividend yield of 1.6%, positioning it as a cost-effective defensive play amid market volatility. Recent news highlights strong sector inflows and defensive demand, with earnings from key holdings like UnitedHealth showing resilience despite Medicaid pressures.

The outlook for XLV is positive, supported by its defensive characteristics and institutional interest, though risks include regulatory pressures and sector-specific volatility. Investors may find value in its diversification and steady performance, but should monitor healthcare policy developments and earnings trends for sustained growth.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Enveric Biosciences Inc

Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.

Read more on ENVB

About Health Care Select Sector SPDR Fund

In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.

Read more on XLV